EDIT stock forecast, quote, news & analysis
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases... Show more
Editas Medicine (EDIT) Stock Analysis: EDIT-401 Milestone Sharpens Focus on 2027 Clinical Data
Key Takeaways
- EDIT gained roughly 3.6% over the last 30 days, moving from about $2.51 to around $2.60.
- The advance followed approval to initiate the Phase 1/2 Strive trial of EDIT-401 in Australia, the company's first in vivo gene-editing program to reach the clinic.
- Wells Fargo upgraded the stock to Overweight and raised its price target to $6 from $4 on the trial clearance.
- The broader quarter was largely rangebound, with shares trading roughly between $2.24 and $3.30 amid biotechnology sector volatility.
- Key near-term catalysts include initial safety and tolerability data from EDIT-401 expected in the first quarter of 2027 and a preclinical data presentation at AHA Scientific Sessions 2026.
- Editas has no approved products and remains pre-revenue, making clinical execution and cash runway central to the investment thesis.
- For additional detail, review Editas Medicine's Price Targets, Earnings, and Forecast pages.
- Explore Trending AI Robots to see how AI-driven trading strategies are positioning across the market.
Current Market Snapshot
Editas Medicine (EDIT) has traded in a relatively narrow band over the past month, ending the period modestly higher. The stock rose from a closing level of about $2.51 on September 28 to approximately $2.60 by October 27, a gain of roughly 3.6%. The upward bias came primarily from a single catalyst: regulatory clearance to begin human dosing of the company's lead in vivo candidate, EDIT-401.
Zooming out, the three-month picture is flatter. Shares opened the quarter near $2.62 and finished near $2.60, but that stability masked meaningful intra-period swings. The stock climbed toward $3.30 in late August before retreating through September and testing the low $2.20s in mid-October, reflecting the broader volatility that has characterized the clinical-stage biotech and gene-editing sector.
Editas Medicine (EDIT) Business Overview and Competitive Position
Editas Medicine is a Cambridge, Massachusetts-based genome editing company that develops CRISPR-based medicines for serious diseases. The company is an exclusive licensee of the Broad Institute's Cas12a patent estate and of Broad Institute and Harvard University's Cas9 patent estates for human medicines, giving it a foundational intellectual-property position in the field.
Following a strategic pivot in late 2024, Editas discontinued development of its ex vivo sickle cell and beta-thalassemia candidate reni-cel and reduced its workforce by roughly 65% to concentrate resources on in vivo gene editing, where therapies are delivered directly into the body. Its lead program, EDIT-401, is an in vivo medicine designed to edit the LDLR gene to increase LDL-receptor expression and durably lower LDL cholesterol in patients with heterozygous familial hypercholesterolemia. The company operates in a competitive landscape alongside peers such as CRISPR Therapeutics, Intellia Therapeutics, and Beam Therapeutics.
Recent Developments Driving EDIT
The most significant recent catalyst came on October 8, when Editas announced it received Human Research Ethics Committee approval and completed the Clinical Trial Notification process with Australia's Therapeutic Goods Administration to initiate the Phase 1/2 Strive clinical trial of EDIT-401. The submission is also under review in New Zealand. The company has selected five clinical trial sites across Australia and New Zealand and expects to begin patient dosing this year.
The regulatory milestone prompted Wells Fargo to upgrade EDIT to Overweight from Equal Weight and lift its price target to $6 from $4, citing a differentiated approach to lowering LDL cholesterol and the potential for a value inflection upon clinical proof-of-concept. Preclinical data supporting the program have shown roughly 90% or greater reductions in LDL cholesterol and other atherogenic lipoproteins in non-human primates.
Additional catalysts included the appointment of Dan Ory, M.D., as Chief Medical Officer in early September and presentations at the European Society of Gene and Cell Therapy Congress in late October. The company also announced that new preclinical durability data for EDIT-401 would be presented at the American Heart Association Scientific Sessions in November.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots drawn from a platform that operates hundreds of automated strategies across thousands of tickers. Only the top-performing and most relevant bots are featured in this section, giving traders a focused view of strategies that are currently standing out. The bots vary widely in approach, holding period, and performance metrics, so users can filter and compare strategies that match their own risk tolerance and objectives. For investors tracking biotechnology and gene-editing names alongside the broader market, the section offers a data-driven way to observe how automated systems are navigating shifting conditions.
2026 Outlook and What Investors Should Watch
Looking ahead, Editas' investment narrative centers on clinical execution for EDIT-401. Investors will monitor the start of patient dosing, the November preclinical data presentation at AHA Scientific Sessions 2026, and the initial safety and tolerability results expected in the first quarter of 2027, with topline data from the dose-finding portion of the trial anticipated later in 2027.
Because the company is pre-revenue, cash runway and spending discipline remain important factors, along with the pace of enrollment across the Australian and New Zealand trial sites. Broader sentiment toward clinical-stage biotechnology and gene-editing equities, regulatory developments, and competitive progress from peers in the in vivo editing space will also influence the stock. Analyst consensus has reflected a generally favorable view, though the shares remain sensitive to binary clinical and financing events.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
EDIT's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for EDIT turned positive on October 27, 2026. Looking at past instances where EDIT's MACD turned positive, the stock continued to rise in 39 of 48 cases over the following month. The odds of a continued upward trend are 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on EDIT as a result. In 68 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
Following a +22.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in 180 of 225 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
EDIT moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
EDIT broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for EDIT entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 36 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 55 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.895) is normal, around the industry mean (3.162). P/E Ratio (-4.045) is within average values for comparable stocks, (-1.064). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.622) among similar stocks. P/S Ratio (5.855) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 55 (best 1 - 100 worst), indicating steady price growth. EDIT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which translates genome editing technology into a novel class of human therapeutics
Industry Biotechnology